BMS-309403 sodium is a potent, orally active, selective inhibitor of the adipocyte fatty acid binding protein (FABP4, aP2), demonstrating inhibitory constants (K i ) of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. It operates by competitively binding to the fatty-acid-binding pocket of the protein, thereby impeding the attachment of endogenous fatty acids. This compound has been shown to enhance endothelial function both in apolipoprotein E-deficient mice and cultured human endothelial cells, underlining its potential therapeutic benefits [1] [2] [3].